“At UCB, we have made it a priority to develop a true understanding of the real world challenges for people living with severe rheumatologic conditions and to determine the best solutions. The availability of the AutoClicks® Prefilled Pen will allow us to provide different administration options for patients treated with CIMZIA®. Patients have personal preferences for self-injection devices depending on their experience and individual needs, so having a prefilled pen and syringe will better support patients,” said Emmanuel Caeymaex, Head of Immunology and Executive Vice President at UCB, Immunology Patient Value Unit, UCB.
UCB is committed to providing value to patients and meeting their unique needs. As part of this commitment, UCB continued its partnership with OXO, a company known for thoughtful, consumer friendly designs, to develop the AutoClicks® Prefilled Pen, based on core technology licensed from Bespak. The AutoClicks® Prefilled Pen provides a button-free delivery system and a wide non-slip grip that keeps patient hand disability in mind. It has a large viewing window that shows the progress of the injection and it makes a clicking noise at the start of the injection and again when the injection is complete, giving patients confidence to know they have received their full dose of CIMZIA®.
Research was conducted to ensure that the AutoClicks® Prefilled Pen would meet the needs of patients living with autoimmune diseases like rheumatoid arthritis. In a comparative usability study with 76 moderate to severe rheumatoid arthritis (RA) patients simulating an injection using an injection pad, the RA patients gave the highest rankings to the AutoClicks® Prefilled Pen as the most preferred prefilled pen. Patients in the study also evaluated the AutoClicks® Prefilled Pen on a seven point scale for its ease of use and their willingness to use it in the future, giving it the highest score on the scale compared to Enbrel® (etanercept), Humira® (adalimumab) and Simponi® (golimumab) anti-TNF prefilled pens (p˂0.05).2 The patients in the study had no prior experience using an anti-TNF prefilled pen. All identification was removed from the prefilled pen devices and the instructions for use. Devices tested at time of study were approved for use in the UK.1